"Managing Inhibitors in Hemophilia Treatment” is the focus of the latest educational opportunity from Medscape. This activity, which became available on October 26, 2015, is part of the online series, Clinical Advances in Hemophilia: Management for Life. The overarching purpose of the program is to increase the knowledge, skills and competence of clinicians in providing individualized management of hemophilia.
The series is presented through a strategic collaboration between the National Hemophilia Foundation and Medscape Education Hematology, and supported by an independent educational grant from Biogen. After completing the activities within this program, available for one year from their release date, those eligible may receive free continuing education (CE) or continuing medical education (CME) credits.
“Managing Inhibitors in Hemophilia Treatment” is intended for hematologists, pediatricians and other healthcare professionals who treat patients with hemophilia.
Upon completion of the activity, participants will be able to:
1. Describe the incidence and severity of inhibitors (high-titer vs low-titer inhibitors, and how each are treated differently) after the use of standard and prolonged half-life factor products
2. Evaluate strategies for managing patients who develop inhibitors with hemophilia treatment
Managing Inhibitors in Hemophilia Treatment CME
Christine L. Kempton, MD, MSc
CME Released: 10/26/2015; Valid for credit through 10/26/2016
Access this and other available educational activities by visiting Medscape.org, where registration is straightforward and free of charge. Once registered, you may access Clinical Advances in Hemophilia: Management for Life.
